(+)-LARICIRESINOL manufacturers
- Lariciresinol
-
- $433.00 / 5mg
-
2026-04-22
- CAS:27003-73-2
- Min. Order:
- Purity: 99.84%
- Supply Ability: 10g
- Lariciresinol
-
- $0.00 / 5mg
-
2023-02-24
- CAS:27003-73-2
- Min. Order: 5mg
- Purity: ≥98%(HPLC)
- Supply Ability: 10 g
- (+)-LARICIRESINOL
-
- $1.00 / 1KG
-
2020-01-13
- CAS:27003-73-2
- Min. Order: 1KG
- Purity: 98%-99.9%
- Supply Ability: 200kg
|
| | (+)-LARICIRESINOL Basic information |
| Product Name: | (+)-LARICIRESINOL | | Synonyms: | (2S)-2α-(3-Methoxy-4-hydroxyphenyl)-4β-(3-methoxy-4-hydroxybenzyl)tetrahydrofuran-3β-methanol;(2S)-Tetrahydro-2α-(4-hydroxy-3-methoxyphenyl)-4β-[(4-hydroxy-3-methoxyphenyl)methyl]-3β-furanmethanol;2-Methoxy-4-[[(2S)-tetrahydro-2α-(3-methoxy-4-hydroxyphenyl)-3β-(hydroxymethyl)furan-4β-yl]methyl]phenol;2α-(4-Hydroxy-3-methoxyphenyl)-3β-(hydroxymethyl)-4β-(4-hydroxy-3-methoxybenzyl)tetrahydrofuran;Laricericinol;Nsc329247;Lariciresil;(+)-LARICIRESINOL | | CAS: | 27003-73-2 | | MF: | C20H24O6 | | MW: | 360.4 | | EINECS: | | | Product Categories: | Miscellaneous Natural Products | | Mol File: | 27003-73-2.mol |  |
| | (+)-LARICIRESINOL Chemical Properties |
| Melting point | 167-168 °C | | Boiling point | 568.4±50.0 °C(Predicted) | | density | 1.261±0.06 g/cm3(Predicted) | | storage temp. | Sealed in dry,Room Temperature | | solubility | Soluble in Chloroform,Dichloromethane,Ethyl Acetate,DMSO,Acetone,etc. | | pka | 9.91±0.35(Predicted) | | form | Powder | | color | White to off-white | | BRN | 4560057 | | Major Application | metabolomics
vitamins, nutraceuticals, and natural products | | InChI | InChI=1S/C20H24O6/c1-24-18-8-12(3-5-16(18)22)7-14-11-26-20(15(14)10-21)13-4-6-17(23)19(9-13)25-2/h3-6,8-9,14-15,20-23H,7,10-11H2,1-2H3/t14-,15-,20+/m0/s1 | | InChIKey | MHXCIKYXNYCMHY-AUSJPIAWSA-N | | SMILES | O1C[C@H](CC2=CC=C(O)C(OC)=C2)[C@H](CO)[C@H]1C1=CC=C(O)C(OC)=C1 | | LogP | 1.640 (est) |
| Hazard Codes | N | | Risk Statements | 50 | | Safety Statements | 61 | | RIDADR | UN 3077 9 / PGIII | | WGK Germany | 3 | | Storage Class | 11 - Combustible Solids | | Hazard Classifications | Aquatic Acute 1 |
| | (+)-LARICIRESINOL Usage And Synthesis |
| Uses | (+)-Lariciresinol is used in biological studies as an anti-tumor-initiating effects of phenolic compounds isolated from the bark of Picea jezoensis var. jezoensis to evaluate the pharmacological activity. | | Definition | ChEBI: (+)-lariciresinol is a lignan that is tetrahydrofuran substituted at positions 2, 3 and 4 by 4-hydroxy-3-methoxyphenyl, hydroxymethyl and 4-hydroxy-3-methoxybenzyl groups respectively (the 2S,3R,4R-diastereomer). It has a role as an antifungal agent and a plant metabolite. It is a member of oxolanes, a member of phenols, a lignan, a primary alcohol and an aromatic ether. It is an enantiomer of a (-)-lariciresinol. | | Biological Activity | Lariciresinol is a potent dietary antioxidant and a radical scavenger by potentially chelating catalytic Fe2+ ions. It exerts antimicrobial effects against foodborne pathogens S. aureus and E. coli O157:H7. Lariciresinol is an effective anticancer agent th at inhibits cell proliferation and induces apoptosis in human HepG2 cells in vitro. It also displays anti-inflammatory and anti-diabetic effects in vitro and in vivo studies respectively. | | in vivo | Lariciresinol (10 mg/kg, p.o., 3 weeks) displays anti-diabetic activity in Streptozotocin (HY-13753)-treated diabetic mice[6].
Lariciresinol (10-30 mg/kg, i.p., 28 days) inhibits complete Freund's adjuvant-induced arthritis in rats by regulating TGF-β and NF-κB pathways[7].
Lariciresinol (3-15 mg/kg body weight, p.o., daily, 9 weeks (tumor bearing rats); 20-100 ppm, diet, p.o., 5 weeks (E2-maintained ovariectomized athymic mice bearing orthotopic MCF-7 tumors)) inhibits tumor growth and tumor angiogenesis in mammary tumor bearing rats and E2-maintained ovariectomized athymic mice bearing orthotopic MCF-7 tumors[8].
| Animal Model: | Streptozotocin (HY-13753)-treated diabetic mice[6] | | Dosage: | 10 mg/kg | | Administration: | Oral gavage (p.o.), 3 weeks | | Result: | Decreased blood glucose levels and increased insulin levels.
Improved pancreatic islet size, increased GLUT4 expression.
Enhanced insulin signaling in skeletal muscle.
|
| | target | VEGFR | Antifection |
| | (+)-LARICIRESINOL Preparation Products And Raw materials |
|